<DOC>
	<DOC>NCT01360021</DOC>
	<brief_summary>This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.</brief_summary>
	<brief_title>New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male or female 12 years and above Clinical diagnosis of asthma according to the American Thoracic Society definition at least 6 months Prebronchodilator FEV1 ≥ 45% and ≤ 85% of predicted normal Patients with reversible airway obstruction Documented daily use of inhaled corticosteroids for ≥ 3 months History of lifethreatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures during the 2 years prior to Visit 2 Hospitalized during previous 6 months for asthma Required emergency treatment more than once during previous 6 months for an asthmarelated condition Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment Respiratory infection affecting the asthma within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>